GuidelineClinical pharmacology and therapeutics2015
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.
Guideline in Clinical pharmacology and therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 386 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development of a Population Pharmacokinetic Model to Optimize Tacrolimus Dosing in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplant.
Efficacy of Achieving Early Target Trough Levels of Tacrolimus Using CYP3A5 Guided Dosing Versus Weight-based Dosing in a Multi-ethnic Population of Kidney Transplant Recipients in Singapore
Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus
Who cites it
386 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Vietnamese pharmacogenomic variation in global context: a systematic review and meta-analysis for clinical implementation.Frontiers in pharmacology · 2026Pooled it
- Clinical Pharmacogenetic Testing and Application: 2024 Updated Guidelines by the Korean Society for Laboratory Medicine.Annals of laboratory medicine · 2025Guideline
- Polymorphisms inFrontiers in pharmacology · 2025Pooled it
- [Selection of pharmacogenomic variants and methodology for their use in community pharmacy].Farmaceuticos comunitarios · 2024Pooled it
- Population pharmacokinetic analyses of tacrolimus in non-transplant patients: a systematic review.European journal of clinical pharmacology · 2023Pooled it
- Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease.Nature communications · 2023Pooled it
- Effects ofFrontiers in pharmacology · 2023Pooled it
- Effect of High-Fat Diet on Pharmacokinetics and Incidence of Adverse Reactions of Tacrolimus in Healthy Chinese Participants.Clinical pharmacology in drug development · 2026Trial
- The effect of the very low dosage diltiazem on tacrolimus exposure very early after kidney transplantation: a randomized controlled trial.Scientific reports · 2022Trial
- CYP3A and CYP2D6 variability in antimalarial pharmacokinetics and pharmacogenetics across populations: a narrative review.Malaria journal · 2026Review
- Nudix hydrolase 15 deficiency and azathioprine toxicity in a liver transplant recipient: A case report.JPGN reports · 2026Article
- The Asian perspective on xenotransplantation: bridging the organ gap through regional collaboration and tailored clinical protocols.Clinical transplantation and research · 2026Review
- Post-transplant atrial tachyarrhythmias: Epidemiology, mechanisms, outcomes, and management across solid organs.World journal of transplantation · 2026Review
- Concentration-to-Dose Ratio Differences Between Once-Daily Tacrolimus Formulations: A Five-Year Real-World Pharmacokinetic Study in Kidney Transplantation.European journal of drug metabolism and pharmacokinetics · 2026Article
- Review
- Real-world pharmacogenomics-guided antihypertensive treatment response in clinical practice underrepresented population: implications for precision prescribing and medication safety.European journal of clinical pharmacology · 2026Observational
- Genetic PolymorphismsPharmaceuticals (Basel, Switzerland) · 2026Article
- A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics.Clinical pharmacokinetics · 2026Review
- Differences in Early Tacrolimus Exposure in Kidney Transplant Recipients With and Without CYP3A5 Genotype-Guided Tacrolimus Dosing.Clinical and translational science · 2026Article
- Precision Dosing of Tacrolimus in Liver Transplantation: Integrating Donor-Recipient CYP3A5 Pharmacogenomics and Drug Interactions.CPT: pharmacometrics & systems pharmacology · 2026Article
326 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose-adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.